Karol Sokolowski

Karol Sokolowski

Auto-generated profile, based on publicly available information

Karol Sokolowski

ClostraBio, Inc., Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
YHYanqin Huang
Yanqin Huang
KSKarol Sokolowski
Karol Sokolowski
ARAmisha Rana
Amisha Rana
NSNidhi Singh
Nidhi Singh
JWJiping Wang
Jiping Wang
ZBZackery Bulman
Zackery Bulman
Antibiotic combinations, including ceftazidime/avibactam (CAZ/AVI), are frequently employed to combat KPC-producing Klebsiella pneumoniae (KPC-Kp), though such combinations have not been rationally optimized. Clinical KPC-Kp isolates with common genes encoding aminoglycoside-modifying enzymes (AMEs), aac(6′)-Ib′ or aac(6′)-Ib , were used in static time-kill assays ( n = 4 isolates) and the hollow-fiber infection model (HFIM; n = 2 isolates) to evaluate the activity of gentamicin, amikacin, and CAZ/AVI alone and in combinations.

11 June 2021 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
KSKarol Sokolowski
Karol Sokolowski
HPHai M. Pham
Hai M. Pham
EWEric Wenzler
Eric Wenzler
RGRichard A. Gemeinhart
Richard A. Gemeinhart
Purpose Skin and soft tissue infections are increasingly prevalent and often complicated by potentially fatal therapeutic hurdles, such as poor drug perfusion and antibiotic resistance. Delivery vehicles capable of versatile loading may improve local bioavailability and minimize systemic toxicities yet such vehicles are not clinically available. Therefore, we aimed to expand upon the use of glutathione-conjugated poly(ethylene glycol) GSH-PEG hydrogels beyond protein delivery and evaluate the ability to deliver traditional therapeutic molecules. Methods PEG and GSH-PEG hydrogels were prepared using ultraviolet light (UV)-polymerization. Hydrogel loading and release of selected drug candidates was examined using UV-visible spectrometry. Therapeutic molecules and GST-fusion protein loading was examined using UV-visible and fluorescent spectrometry. Efficacy of released meropenem was assessed against meropenem-sensitive and -resistant P. aeruginosa in an agar diffusion bioassay. Results For all tested agents, GSH-PEG hydrogels demonstrated time-dependent loading whereas PEG hydrogels did not. GSH-PEG hydrogels released meropenem over 24 h. Co-loading of biologic and traditional therapeutics into a single vehicle was successfully demonstrated. Meropenem-loaded GSH-PEG hydrogels inhibited the growth of meropenem-sensitive and resistant P. aeruginosa isolates. Conclusion GSH ligands within GSH-PEG hydrogels allow loading and effective delivery of charged therapeutic agents, in addition to biologic therapeutics. Graphical abstract

1 January 2026 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
SASonia Alavi
Sonia Alavi
KSKarol Sokolowski
Karol Sokolowski
CDCatherine F Dial
Catherine F Dial
ZBZackery Bulman
Zackery Bulman
RGRichard A Gemeinhart
Richard A Gemeinhart
Systemic antibiotics are the standard of care for acute bacterial skin and skin structure infections (ABSSSI), but low drug perfusion at the site of infection and higher rates of antibiotic...

7 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AGAzure D. Grant
Azure D. Grant
BMBrian Meehan
Brian Meehan
MKMarie Crisel E. Krupa
Marie Crisel E. Krupa
MRMiguel A. Rosales
Miguel A. Rosales
KSKarol Sokolowski
Karol Sokolowski
NCNoah Craft
Noah Craft
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).